ValuEngine Downgrades Aphria (NYSE:APHA) to Hold

Share on StockTwits

ValuEngine lowered shares of Aphria (NYSE:APHA) from a buy rating to a hold rating in a research note released on Thursday morning, ValuEngine reports.

APHA has been the topic of a number of other reports. Cantor Fitzgerald started coverage on shares of Aphria in a report on Tuesday, November 5th. They set an overweight rating and a $10.40 target price on the stock. Pi Financial set a $9.00 price target on shares of Aphria and gave the stock a buy rating in a research note on Tuesday, October 15th. CIBC restated a sell rating and issued a $6.50 price target on shares of Aphria in a research note on Wednesday, October 16th. Zacks Investment Research lowered Aphria from a buy rating to a hold rating in a research report on Wednesday, November 13th. Finally, Jefferies Financial Group set a $8.30 price objective on Aphria and gave the company a buy rating in a research note on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. Aphria presently has a consensus rating of Buy and an average target price of $11.38.

Shares of APHA opened at $4.72 on Thursday. The stock has a market capitalization of $1.19 billion, a PE ratio of -42.91 and a beta of 2.75. Aphria has a 1 year low of $3.76 and a 1 year high of $10.95. The company’s 50-day simple moving average is $4.83 and its 200-day simple moving average is $6.00.

Aphria (NYSE:APHA) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.10. The business had revenue of $126.10 million during the quarter, compared to analyst estimates of $131.15 million. The business’s quarterly revenue was up 848.1% compared to the same quarter last year. On average, equities research analysts forecast that Aphria will post 0.06 EPS for the current year.

Institutional investors have recently made changes to their positions in the company. Synovus Financial Corp increased its stake in shares of Aphria by 56.9% during the second quarter. Synovus Financial Corp now owns 5,514 shares of the company’s stock worth $39,000 after buying an additional 2,000 shares during the period. Creative Planning grew its holdings in Aphria by 2.9% during the 3rd quarter. Creative Planning now owns 74,332 shares of the company’s stock worth $386,000 after acquiring an additional 2,073 shares in the last quarter. Virtu Financial LLC grew its holdings in Aphria by 14.9% during the 3rd quarter. Virtu Financial LLC now owns 18,365 shares of the company’s stock worth $95,000 after acquiring an additional 2,380 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Aphria by 76.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,248 shares of the company’s stock worth $44,000 after acquiring an additional 2,698 shares in the last quarter. Finally, Sfmg LLC increased its position in shares of Aphria by 15.0% in the 3rd quarter. Sfmg LLC now owns 28,607 shares of the company’s stock valued at $148,000 after purchasing an additional 3,737 shares during the last quarter. 9.89% of the stock is owned by institutional investors and hedge funds.

About Aphria

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Featured Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.